{"id":"NCT05061706","sponsor":"Intra-Cellular Therapies, Inc.","briefTitle":"Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","officialTitle":"A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-30","primaryCompletion":"2024-04-12","completion":"2024-04-12","firstPosted":"2021-09-29","resultsPosted":"2025-03-25","lastUpdate":"2025-05-09"},"enrollment":480,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Lumateperone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lumateperone 42 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.","primaryOutcome":{"measure":"Montgomery-Asberg Depression Rating Scale","timeFrame":"Day 43","effectByArm":[{"arm":"Lumateperone 42 mg","deltaMin":-14.7,"sd":0.56},{"arm":"Placebo","deltaMin":-10.2,"sd":0.54}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["United States","Argentina","Bulgaria","Finland","Germany","Poland","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":242},"commonTop":["Headache","Dizziness","Somnolence","Dry Mouth","Nausea"]}}